See more : Overseas Shipholding Group, Inc. (OSG) Income Statement Analysis – Financial Results
Complete financial analysis of Yumanity Therapeutics, Inc. (YMTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Yumanity Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Tecan Group AG (0QLN.L) Income Statement Analysis – Financial Results
- Van Elle Holdings plc (VANL.L) Income Statement Analysis – Financial Results
- Arch Capital Group Ltd. (ACGLP) Income Statement Analysis – Financial Results
- infinitii ai inc. (IAI.CN) Income Statement Analysis – Financial Results
- Viavi Solutions Inc. (VIAV) Income Statement Analysis – Financial Results
Yumanity Therapeutics, Inc. (YMTX)
About Yumanity Therapeutics, Inc.
Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Yumanity Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Yumanity Therapeutics Reports Second Quarter 2021 Financial Results and Recent Corporate Developments
Yumanity Therapeutics to Present at the 2021 B. Riley Securities' Neuroscience Conference
Yumanity Therapeutics' YTX-7739 Achieved Target Engagement at Doses That Were Generally Well Tolerated in a Phase 1a Multiple Ascending Dose Study in Healthy Volunteers
Yumanity Therapeutics' Glioblastoma Candidate Shows Efficacy In Animal Studies
Yumanity Therapeutics Reports Full Year 2020 Financial Results and Recent Corporate Developments
Yumanity Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
Yumanity Therapeutics Sees Lead Candidate Interim Data From Early-Stage Parkinson's Study By Mid-2021
Yumanity Therapeutics Provides Update on Its Lead Parkinson's Disease Clinical Program, YTX-7739
Yumanity Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference
Source: https://incomestatements.info
Category: Stock Reports